| Literature DB >> 35431911 |
Prashant Kesharwani1, Rahul Chadar1, Afsana Sheikh1, Waleed Y Rizg2, Awaji Y Safhi3.
Abstract
Cluster of differentiation 44 (CD44) is a cell surface glycoprotein overexpressed in varieties of solid tumors including pancreatic, breast, ovary, brain, and lung cancers. It is a multi-structural glycoprotein of the cell surface which is majorly involved in cell proliferation, cell-to-cell interaction, cellular migration, inflammation, and generation of immune responses. Numerous studies focus on the development of nanocarriers for active targeting of the CD44 receptor to improve efficacy of targeting chemotherapy and achieve precise chemotherapy by defining the release, uptake, and accumulation of therapeutic agents. The CD44 receptor has a selective binding affinity towards hyaluronic and chondroitin sulfate (CS). Taking this into consideration, this review focused on the role of CD44 in cancer and its therapy using several nanocarriers such as polymeric/non-polymeric nanoparticles, dendrimer, micelles, carbon nanotubes, nanogels, nanoemulsions etc., for targeted delivery of several chemotherapeutic molecules and nucleic acid. This review also illuminates the role of hyaluronic acid (HA) in cancer therapy, interaction of HA with CD44, and various approaches to target CD44-overexpressed neoplastic cells.Entities:
Keywords: CD44; anticancer therapy; gene delivery; hyaluronic acid; nanocarrier; targeted drug delivery
Year: 2022 PMID: 35431911 PMCID: PMC9008230 DOI: 10.3389/fphar.2021.800481
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810